Latest News for: nls

Edit

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy (Form 6-K) (NLS Pharmaceutics Ltd)

Public Technologies 12 Feb 2026
). NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy. Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset ... NLS Pharmaceutics Ltd.
Edit

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences (Form 6-K) (NLS Pharmaceutics Ltd)

Public Technologies 29 Jan 2026
). NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences ... Zurich, Switzerland - January 29, 2026 - NewcelX Ltd. (NASDAQ ... Corporate Presentation. About NewcelX Ltd. NewcelX Ltd ... NLS Pharmaceutics Ltd.
Edit

NLS changes 2026 calendar to aid Verstappen's Nurburgring 24 Hours bid

Autosport 26 Jan 2026
The Nurburgring Langstrecken-Serie (NLS) is adjusting its 2026 schedule to make ...
Edit

Mercedes makes NLS request to aid Verstappen's Nurburgring 24h appearance

Autosport 17 Jan 2026
Max Verstappen's start at the Nurburgring 24 Hours now depends solely on an NLS ...
Edit

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell–Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression (Form 6-K) (NLS Pharmaceutics Ltd)

Public Technologies 12 Jan 2026
). NewcelX Announce Positive Results from International Collaborative Study Exploring. Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes. Without Immune Suppression ... (Nasdaq ... About NewcelX Ltd ... NLS Pharmaceutics Ltd.
Edit

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board (Form 6-K) (NLS Pharmaceutics Ltd)

Public Technologies 05 Jan 2026
). NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader. in Diabetes Innovation, to Its Scientific Advisory Board. Zurich, Switzerland and Ness Ziona, Israel - January 5th, 2026 - NewcelX Ltd. (Nasdaq ... Dr ... Boisdron ... (Nasdaq ... NLS Pharmaceutics Ltd.
Edit

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China (Form 6-K) (NLS Pharmaceutics Ltd)

Public Technologies 11 Dec 2025
). NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China ... Zurich, Switzerland - December 11th - NewcelX Ltd. (Nasdaq ... Key Patent Information ● Priority. Europe Patent Application No ... 2 ... NLS Pharmaceutics Ltd.
Edit

Report Of Foreign Private Issuer (Form 6-K) (NLS Pharmaceutics Ltd)

Public Technologies 20 Nov 2025
). CONTENTS. In connection with the closing of the merger (the "Merger") between NewCelX Ltd. (the "Company") (formerly known as NLS Pharmaceutics Ltd.) and Kadimastem Ltd ... 1. EXHIBIT INDEX Exhibit No ... 3 ... NLS Pharmaceutics Ltd ... (noodl.
Edit

Notice of Effectiveness (Form EFFECT) (NLS Pharmaceutics Ltd)

Public Technologies 19 Nov 2025
) UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. Notice of Effectiveness ... NLS Pharmaceutics Ltd.
Edit

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute (Form 6-K) (NLS Pharmaceutics Ltd)

Public Technologies 17 Nov 2025
). NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute ... (Nasdaq ... Prof ... In his role on the SAB of NewcelX, Prof ... Prof. Shefner commented ... NLS Pharmaceutics Ltd.
  • 1

Article Search

tools
×
×
×
×